The launch of Altos Labs represented something of a coming of age for the business of trying to prolong youth.
With a vast $3bn of financial backing, GSK’s former chief scientific officer in charge and a mission to rejuvenate the human body, the California-based biotech in 2022 embarked on research on how to reverse disease and restore healthy cells — and kicked off serious interest in longevity.
Of course, researchers have been studying the ageing process for decades and interest in treatments and cures stretches back millennia. By the 2010s, investors had started to test the water with companies such as Calico Life Sciences and Cambrian Biopharma. But it was the Altos Labs deal in 2022 that marked a new level of investor commitment.
您已阅读10%（742字），剩余90%（6905字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。